MEI Pharma Inc (MEIP)
MEI Pharma is a clinical-stage pharmaceutical company focused on developing cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.
Company Name: |
MEI Pharma Inc |
Website: |
www.meipharma.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding MEIP: |
3 |
Total Market Value Held by ETFs: |
$1.16M |
Total Market Capitalization: |
$26.00M |
% of Market Cap. Held by ETFs: |
4.45% |
|
|
March 29, 2024 6:13 AM Eastern
Buy (3.00 out of 4)
27th percentile
|
|